Steve Qin

Dr. Steve Qin

1. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Neoplasia
Verified
Journal Article
Open access
DCDarshan Shimoga Chandrashekar
Darshan Shimoga Chandrashekar
SKSanthosh Kumar Karthikeyan
Santhosh Kumar Karthikeyan
PKPraveen Kumar Korla
Praveen Kumar Korla
HPHenalben Patel
Henalben Patel
ASAhmedur Rahman Shovon
Ahmedur Rahman Shovon
Sooryanarayana VaramballySooryanarayana Varambally
Sooryanarayana Varambally
Cancer genomic, transcriptomic, and proteomic profiling has generated extensive data that necessitate the development of tools for its analysis and dissemination. We developed UALCAN to provide a portal for easy exploring, analyzing, and visualizing these data, allowing users to integrate the data to better understand the gene, proteins, and pathways perturbed in cancer and make discoveries. UALCAN web portal enables analyzing and delivering cancer transcriptome, proteomics, and patient survival data to the cancer research community. With data obtained from The Cancer Genome Atlas (TCGA) project, UALCAN has enabled users to evaluate protein-coding gene expression and its impact on patient survival across 33 types of cancers. The web portal has been used extensively since its release and received immense popularity, underlined by its usage from cancer researchers in more than 100 countries. The present manuscript highlights the task we have undertaken and updates that we have made to UALCAN since its release in 2017. Extensive user feedback motivated us to expand the resource by including data on a) microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and promoter DNA methylation from TCGA and b) mass spectrometry-based proteomics from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). UALCAN provides easy access to pre-computed, tumor subgroup-based gene/protein expression, promoter DNA methylation status, and Kaplan-Meier survival analyses. It also provides new visualization features to comprehend and integrate observations and aids in generating hypotheses for testing. UALCAN is accessible at http://ualcan.path.uab.edu

1 August 2007 in Current Biology
Verified
Journal Article
Closed access
GBGuido Bommer
Guido Bommer
IGIsabelle Gerin
Isabelle Gerin
YFYing Feng
Ying Feng
AKAndrew J. Kaczorowski
Andrew J. Kaczorowski
RKRork Kuick
Rork Kuick
EFEric R. Fearon
Eric R. Fearon

23 April 2014 in Nature
Verified
Journal Article
Open access
PDF file
IAIrfan A. Asangani
Irfan A. Asangani
VDVijaya L. Dommeti
Vijaya L. Dommeti
XWXiaoju Wang
Xiaoju Wang
RMRohit Malik
Rohit Malik
MCMarcin Cieslik
Marcin Cieslik
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
Small-molecule compounds that target the BET domain in proteins such as BRD4 have recently been identified as potential anticancer agents; here, the efficacy of the BRD4-targeting compound JQ1 is demonstrated in castration-resistant prostate cancer driven by deregulated androgen receptor action. Small-molecule compounds that target the BET domain chromatin factors such as BRD4 have recently come to the fore as potential anticancer agents in several cancer types. Arul Chinnaiyan and colleagues now demonstrate efficacy of the BRD4-targeting compound JQ1 in castration-resistant prostate cancer driven by deregulated androgen receptor action. They see inhibition of tumour xenograft growth in vivo in a mouse model through a mechanism that appears to endow JQ1 with greater potency than classical androgen receptor antagonists. Castration can control some prostate cancers by reducing levels of male sex hormone levels but tumours can become resistant. The prognosis for castration-resistant prostate cancers is generally poor. This work identifies the targeting of co-activators or mediators of androgen receptor transcriptional signalling as a possible alternative therapeutic strategy. Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signalling1,2,3. Despite the success of recently approved therapies targeting AR signalling, such as abiraterone4,5,6 and second-generation anti-androgens including MDV3100 (also known as enzalutamide)7,8, durable responses are limited, presumably owing to acquired resistance. Recently, JQ1 and I-BET762 two selective small-molecule inhibitors that target the amino-terminal bromodomains of BRD4, have been shown to exhibit anti-proliferative effects in a range of malignancies9,10,11,12. Here we show that AR-signalling-competent human CRPC cell lines are preferentially sensitive to bromodomain and extraterminal (BET) inhibition. BRD4 physically interacts with the N-terminal domain of AR and can be disrupted by JQ1 (refs 11, 13). Like the direct AR antagonist MDV3100, JQ1 disrupted AR recruitment to target gene loci. By contrast with MDV3100, JQ1 functions downstream of AR, and more potently abrogated BRD4 localization to AR target loci and AR-mediated gene transcription, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity. In vivo, BET bromodomain inhibition was more efficacious than direct AR antagonism in CRPC xenograft mouse models. Taken together, these studies provide a novel epigenetic approach for the concerted blockade of oncogenic drivers in advanced prostate cancer.

5 December 2010 in Nature Methods
Verified
Journal Article
Open access
PDF file
HCHyungwon Choi
Hyungwon Choi
BLBrett Larsen
Brett Larsen
ZLZhen-Yuan Lin
Zhen-Yuan Lin
ABAshton Breitkreutz
Ashton Breitkreutz
DMDattatreya Mellacheruvu
Dattatreya Mellacheruvu
ANAlexey I Nesvizhskii
Alexey I Nesvizhskii
A statistical framework for assigning confidence scores for protein-protein interaction data generated via affinity purification–mass spectrometry, called significance analysis of interactome (SAINT) is described. We present 'significance analysis of interactome' (SAINT), a computational tool that assigns confidence scores to protein-protein interaction data generated using affinity purification–mass spectrometry (AP-MS). The method uses label-free quantitative data and constructs separate distributions for true and false interactions to derive the probability of a bona fide protein-protein interaction. We show that SAINT is applicable to data of different scales and protein connectivity and allows transparent analysis of AP-MS data.

21 May 2010 in Science
Verified
Journal Article
Closed access
PDF file
ABAshton Breitkreutz
Ashton Breitkreutz
HCHyungwon Choi
Hyungwon Choi
JSJeffrey R. Sharom
Jeffrey R. Sharom
LBLorrie Boucher
Lorrie Boucher
VNVictor Neduva
Victor Neduva
MTMike Tyers
Mike Tyers
Budding Yeast Kinome Revealed: Covalent modification of proteins by phosphorylation is a primary means by which cells control the biochemical activities and functions of proteins. To better understand the full spectrum of cellular control mechanisms mediated by phosphorylation, Breitkreutz et al. (p. 1043 ; see the Perspective by Levy et al. ) used mass spectrometry to identify proteins that interacted with the complete set of protein kinases from budding yeast and with other molecules, including phosphatases, which influence phosphorylation reactions. The results reveal a network of interacting protein kinases and phosphatases, and analysis of other interacting proteins suggests previously undiscovered roles for many of these enzymes.

1 May 2010 in Cancer Cell
Verified
Journal Article
Closed access
JYJindan Yu
Jindan Yu
JYJianjun Yu
Jianjun Yu
RMRam-Shankar Mani
Ram-Shankar Mani
QCQi Cao
Qi Cao
CBChad J. Brenner
Chad J. Brenner
ACArul M. Chinnaiyan
Arul M. Chinnaiyan